Affiliation:
1. College of Chemistry and Chemical
Engineering, Shaanxi University of Science and Technology, Xi’an 710021, China
2. School of Environmental and Chemical Engineering, Xi’an Polytechnic University, Xi’an 710048, China
3. Xi’an Key
Laboratory of Textile Chemical Engineering Auxiliaries, Xi’an 710048, China
Abstract
Background:
The high mortality rate of cancer is endangering human health, and the research
and development of new anticancer drugs have the attention of scientists worldwide. Sulfonamides have
become the focus of anticancer drug research. 1,2,3-triazole compounds can inhibit the formation of a
variety of tumor cells. Based on the excellent antitumor activity exhibited by the 1,2,3-triazole compound
skeleton, the sulfonamide moiety in the sulfonamide structure can be introduced into the triazole compound
skeleton to obtain highly active anticancer drugs.
Methods:
The Topomer CoMFA method was used to study the three-dimensional quantitative structureactivity
relationship of 58 new 1,2,3-triazole compounds with sulfa groups, and a 3D-QSAR model was
obtained.
Results:
The cross-validation coefficient q2 is 0.545, the non-cross-correlation coefficient r2 is 0. 754, r_pred2 is 0.930, the optimal number of principal components N is 4, and the standard estimation error SEE is 0.319. These results show that the model has good internal and external forecasting capabilities. By searching for the R group in the Topomer search module and combining with the more active groups in the existing molecules, 6 new compounds with theoretically higher anti-HL-60 (leukemia cell line) activity are obtained.
Conclusion:
The prediction result of the Topomer CoMFA model is good, and the statistical verification
is effective. The prediction results of ADMET show that the 6 new compounds meet the drug requirements
and are expected to become potential anti-HL-60 inhibitors, providing guidance for the synthesis of
anti-tumor drugs.
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine